Prosecution Insights
Last updated: November 20, 2026
Application No. 18/840,767

USES OF BIFIDOBACTERIUM LONGUM MICROORGANISMS HAVING THE CAPACITY TO DEGRADE BOTH HMO AND PLANT-DERIVED GLYCANS

Non-Final OA §101§102§112§OTHER
Filed
Aug 22, 2024
Priority
Feb 25, 2022 — EU 22158720.7 +2 more
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nestlé S.A.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
562 granted / 921 resolved
+1.0% vs TC avg
Strong +31% interview lift
Without
With
+30.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
43 currently pending
Career history
970
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
36.6%
-3.4% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
27.3%
-12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 921 resolved cases

Office Action

§101 §102 §112 §OTHER
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 8 and 13 – 15, and species A. β-1,4, (β-1,3)-galactose; B. GH35; and NCC 5001 (CNCM -5684) in the reply filed on August 3, 2026 is acknowledged. Claims 8 – 9 and 13 – 15 are pending; claim 9 is withdrawn; claims 8 and 13 – 15 have been considered on the merits. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statements (IDS) submitted on August 22, 2024 and October 9, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Specification The disclosure is objected to because it contains embedded hyperlinks and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Examples include pages 1, 2, 27, 29 and 35. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 8, 13 and 15 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to a method of promoting growth of a “Bifidobacterium longum transitional microorganism” in the gut of an infant of young child. These claims are considered genus claims that encompass a wide array of “transitional microorganisms.” The specification fails to set forth a representative number of examples in order to reasonably verify possession of such a potentially enormous number of microorganisms. The MPEP states that written description for a genus can be achieved by a representative number of species within a broad generic. It is unquestionable that the claims are broad generics, with respect to all Bifidobacterium longum transitional microorganisms that might result from a transition from infancy to “young child” or “young child” to adult. Examples of variations include dietary limitations, age, exposure to pathogenic microorganism, and/or initial gut microbiome of the infant or young child. The possible variations of microorganisms are limitless with potentially millions of subspecies or strains of microorganisms. The instant disclosure identifies a single fecal sample wherein five “transitional microorganisms” were cultured with six or four types of glycan (example 2). Moreover, the sample set is limited an extremely small number of potential microorganisms and also an extremely small number of glycan substrates. The purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed by them. A patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that the inventor invented the claimed invention. Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations" and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." The specification lacks sufficient variety of species of microorganisms to reflect this variance in the genus since the specification does not provide any examples of such a genus of Bifidobacterium longum transitional microorganism.” It is noted that the specification fails to specifically define what these transitional microorganisms might even encompass. Accordingly, the specification fails to provide adequate written description for the genus of “Bifidobacterium longum transitional microorganism” and does not reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed had possession of the entire scope of the claimed invention. Moreover, the specification neither describes the complete structure of a representative number of species, nor describes a representative number of species in terms of partial structure and relevant identifying characteristics. Absent of such teachings and guidance as to the structure and function of these transitional microorganisms, the specification does not describe the claimed genus in such full, clear, concise and exact terms so as to indicate that Applicant had possession of these transitional microorganisms at the time of filing of the present application. Thus, the written description requirement has not been satisfied. Claim 14 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification does not provide clear evidence that the claimed biological material is known and readily available to the public; reproducible; and deposited per the deposit rules under 37 C.F.R 1.801 - 1.809. Every patent must contain a written description of the invention sufficient to enable a person skilled in the art to which the invention pertains to make and use the invention. Where the invention involves a biological material and words alone cannot sufficiently describe how to make and use the invention in a reproducible manner, access to the biological material may be necessary for the satisfaction of the statutory requirements for patentability under 35 U.S.C. 112. Courts have recognized the necessity and desirability of permitting an applicant for a patent to supplement the written disclosure in an application with a deposit of biological material which is essential to meet some requirement of the statute with respect to the claimed invention. See, e.g., Ajinomoto Co. v. Archer-Daniels-Midland Co., 228 F.3d 1338, 1345-46, 56 USPQ2d 1332, 1337-38 (Fed. Cir. 2000), cert. denied, 121 S.Ct. 1957 (2001) (explaining how deposit may help satisfy enablement requirement); Merck and Co., Inc. v. Chase Chemical Co., 273 F. Supp. 68, 155 USPQ 139 (D. N.J. 1967); In re Argoudelis, 434 F.2d 666, 168 USPQ 99 (CCPA 1970). To facilitate the recognition of deposited biological material in patent applications throughout the world, the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure was established in 1977, and became operational in 1981. The Treaty requires signatory countries, like the United States, to recognize a deposit with any depository which has been approved by the World Intellectual Property Organization (WIPO). The deposit rules (37 CFR 1.801 - 1.809) set forth examining procedures and conditions of deposit which must be satisfied in the event a deposit is required. The rules do not address the substantive issue of whether a deposit is required under any particular set of facts. (MPEP 2402). Since the microorganisms “CNCM I-5683, CNCM I-5684, CNCM I-5685, CNCM I-5686 and CNCM I-5687” are recited in the claims, they are essential to the invention recited in those claims. They must therefore be obtainable by a repeatable method set forth in the specification or otherwise be readily available to the public. If the microorganisms are not so obtainable or available, a deposit of the microorganisms may satisfy the requirements of 35 U.S.C. § 112. The specification does not disclose a repeatable process to obtain the microorganisms and it is not apparent if the microorganisms are readily available to the public. Moreover, because no taxonomic information appears in the specification, it is not clear what the microorganisms actually are. However, since a deposit has been made under the terms of the Budapest Treaty, then an affidavit or declaration by Applicants, someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his/her signature and registration number, stating that the specific strain has been deposited under the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. See 37 C.F.R. § 1.808. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8 and 13 – 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 and its dependents are drawn to a method of promoting growth of a microorganism, however are rendered indefinite for reciting “Bifidobacterium longum transitional microorganism” because the phrase is not adequately defined by the claim language or specification. It is unclear if the transitional microorganism must be a strain of B. longum or whether it can be any other species. Clarification is required. Claim 8 is further indefinite for referring to “any of Tables 1 to 3” because claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993) (citations omitted). Claim 13 is indefinite for reciting “recited in in Table 1” because claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993) (citations omitted). In claim 14, line 2, “the Bifidobacterium longum microorganism” lacks proper antecedent basis. It is unclear if the claim is further defining “a Bifidobacterium longum” or “a Bifidobacterium longum transitional microorganism.” Clarification is required. For purposes of examination, the phrase is interpreted as a Bifidobacterium longum transitional microorganism. Claim 15 is indefinite for reciting “an ingredient” because is it unclear of what the glycan substrate the ingredient is. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 8 and 13 – 15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural phenomenon without significantly more. Step 1: Yes. The claims are drawn to a method of promoting growth of a microorganism in the gut of an infant or young child, which is a process. Step 2A, Prong 1: Yes. The claim is drawn to feeding an infant or young child glycan substrates found in food, or feeding infants and young children food, which is a natural phenomenon. The specification indicates that the glycan substrates are found in cereals, grains, seaweed, fungi, legumes fruits and vegetables (Tables 1 – 3) and may be a dietary ingredient, e.g., a raw food (0068 - 0075). In this regard, the claims read on eating any plant or plant product. Step 2A, Prong 2: No. The claims do not recite any additional elements in the method steps that integrate the judicial exception into a practical application. The claims recite the method results in growth of a transitional microorganism, wherein the transitional microorganism is further defined by enzyme production or its average nucleotide identity (ANI) however no other steps are recited beyond feeding a plant product to an infant or young child. Step 2B: No. The claims do not recite any additional elements that amount to more than the judicial exception. The claims recite the method results in growth of a transitional microorganism, wherein the transitional microorganism is further defined by enzyme production or its average nucleotide identity (ANI) however no other steps are recited beyond feeding a plant product to an infant or young child. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 8 and 13 – 15 are rejected under 35 U.S.C. 102a1 and 102a2 as being anticipated by Casaburi et al. (US 2020/0245667). Regarding claims 8 and 13 – 15, Casaburi teaches administering weaning foods to infants such as carrots, banana, peaches, pears and cereal (0018, 0027 – 0028, claims). These foods are identified by applicant as containing β-1,4, (β-1,3)-galactose (applicant’s specification, Table 1) and are considered “ingredients” as recited in claim 15. Although the reference does not teach the method results in promoting growth of Bifidobacterium longum transitional microorganisms, wherein the microorganisms encode the claimed CAZymes, or have an ANI of at least 98% with the recited strains, the method steps are the same. Further, Casaburi teaches feeding breast fed infants which are disclosed to have B. longum in their microbiome (0009, 0016, 0047, example 2). In this regard, by practicing the methods of Casaburi, one is inherently promoting growth of the claimed microorganisms. Claims 8 and 13 – 15 are rejected under 35 U.S.C. 102a1 as being anticipated by Borowitz (2021). Regarding claims 8 and 13 – 15, Borowitz teaches administering weaning foods to infants such as carrots (p.3). Carrots are identified by applicant as containing β-1,4, (β-1,3)-galactose (applicant’s specification, Table 1) and are considered “ingredients” as recited in claim 15. Although the reference does not teach the method results in promoting growth of Bifidobacterium longum transitional microorganisms, wherein the microorganisms encode the claimed CAZymes, or have an ANI of at least 98% with the recited strains, the method steps are the same. In this regard, by practicing the methods of Borowitz, one is inherently promoting growth of the claimed microorganisms. Claims 8 and 13 – 15 are rejected under 35 U.S.C. 102a1 as being anticipated by Brown (2018). Regarding claims 8 and 13 – 15, Brown teaches administering weaning foods to infants such as carrot, banana, pear and peaches (p.6). These foods are identified by applicant as containing β-1,4, (β-1,3)-galactose (applicant’s specification, Table 1, 0085) and are considered “ingredients” as recited in claim 15. Although the reference does not teach the method results in promoting growth of Bifidobacterium longum transitional microorganisms, wherein the microorganisms encode the claimed CAZymes, or have an ANI of at least 98% with the recited strains, the method steps are the same. Further, Brown teaches feeding breast fed or formula fed infants (p.1) which are disclosed by applicant to have B. longum in their microbiome (0006, 0028). In this regard, by practicing the methods of Brown, one is inherently promoting growth of the claimed microorganisms. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Aug 22, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778160
Method and Composition For Reducing Pathogens in Pet Food Using Lactic Acid Bacteria
6y 6m to grant Granted Nov 03, 2026
Patent 12774459
TRUNCATED MODIFIED RECOMBINANT ADAMTS13 AND USES THEREOF
3y 6m to grant Granted Oct 27, 2026
Patent 12773431
COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS
3y 2m to grant Granted Oct 27, 2026
Patent 12766045
Auto-Biodegradable Absorbent Articles
3y 9m to grant Granted Oct 20, 2026
Patent 12766224
DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE
1y 5m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+30.9%)
3y 2m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 921 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month